All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SXC-2023
Therapeutic Area: Psychiatry/Psychology Product Name: SXC-2023
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2020
Details:
The presentation will highlight the continued safety and psychometric activity of the company's lead clinical molecule, SXC-2023, a drug designed to restore cognitive control over repetitive, maladaptive behaviors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PRAX-114
Therapeutic Area: Psychiatry/Psychology Product Name: PRAX-114
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $190.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 15, 2020
Details:
The IPO proceeds will bankroll the phase 2a and phase 2/3 trials of lead asset PRAX-114, an oral modulator of GABAA receptors, according to a securities filing.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Deuterated D-serine
Therapeutic Area: Psychiatry/Psychology Product Name: CTP-692
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The double-blind, randomized, placebo-controlled Phase 2 trial is designed to evaluate the safety and efficacy of CTP-692 as an adjunctive treatment in adult patients with schizophrenia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PRAX-114
Therapeutic Area: Psychiatry/Psychology Product Name: PRAX-114
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 25, 2020
Details:
The company’s pipeline contains its most advanced candidates, PRAX-114 and PRAX-944, which are in Phase 2 development for major depressive disorder/perimenopausal depression and essential tremor, respectively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): XPro1595
Therapeutic Area: Psychiatry/Psychology Product Name: XPro1595
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.9 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2020
Details:
The grant will support a Phase 2 study of XPro1595, a next generation TNF Inhibitor in patients with treatment resistant depression.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Metyrapone,Oxazepam
Therapeutic Area: Psychiatry/Psychology Product Name: EMB-001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
The randomized, double-blind, placebo-controlled Phase 2 clinical trial is supported by funding from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health and will evaluate EMB-001 as a treatment option for patients with cocaine use disorder.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PDC-1421
Therapeutic Area: Psychiatry/Psychology Product Name: ABV-1504
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
The patent application outlines a method for treating major depressive disorder by the patient’s oral administration of a composition containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Evenamide
Therapeutic Area: Psychiatry/Psychology Product Name: NW-3509
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN-166
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: UCLA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
This study was a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the effect of 14 days of ibudilast treatment on heavy drinking days and alcohol neural cue reactivity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cytisinicline
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Lake Street Capital Markets
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 04, 2020
Details:
Achieve intends to use the proceeds from the offering to fund clinical research and development, and for general working capital.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
